Catalyst OrthoScience Appoints Gordon Van Ummersen to Board of Directors

Medtech leader with deep orthopedic extremities experience enhances board depth as shoulder-focused company advances growth and strategic objectives

CATALYST LOGO COLOR GRAY TEXT
CATALYST LOGO COLOR GRAY TEXT

NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the appointment of Gordon Van Ummersen to its board of directors.

“I am pleased to join Catalyst OrthoScience’s board at this important stage of the company’s evolution,” said Van Ummersen. “Catalyst is an exciting shoulder-focused company that has built a compelling platform focused on meaningful differentiation and surgeon partnership, and I look forward to playing an active role in advancing execution across the company’s next phase of growth.”

Van Ummersen has held executive leadership positions across Fortune 100 healthcare and medical technology companies, with a proven track record in driving commercial scale, advancing innovation pipelines, and guiding organizations through pivotal phases of growth and transformation.

“Gordon’s perspective and experience will be invaluable as we execute the next phase of our growth strategy and continue to deepen our relationships within the shoulder community,” said Carl O’Connell, president and chief executive officer of Catalyst. “His leadership aligns perfectly with our commitment to differentiated, surgeon-driven solutions that improve procedural efficiency and outcomes.”

Van Ummersen’s appointment is effective immediately.

About Catalyst OrthoScience Inc.

Catalyst OrthoScience, founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and based in Naples, Fla., is redefining shoulder replacement surgery. With a focus on less invasive techniques, fewer complications, and a more natural-feeling shoulder, Catalyst is breaking away from traditional approaches. Our total shoulder systems are engineered for precision and efficiency – preserving bone and soft tissue while enabling delivery of consistent, reproducible results. With a growing portfolio of issued and pending patents, Catalyst technology is available across the U.S. Learn more at www.catalystortho.com and connect with us on LinkedIn and Instagram.

Contacts

Nicole Nelson

Media Relations

(239) 325-9976

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Stay up-to-date with the latest Newsletters, free of charge.